Novel NIDDM regimen
OwnerLisbeth Tofte Hemmingsen, Peter Giortz Mullerinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of a short-acting oral hypoglycemic agent and to a novel regimen in the treatment of type 2 diabetes in which the endogenous secretion of insulin is stimulated in connection with meals by administering in connection with the meals a short-acting oral hypoglycaemic agent. Also, the present invention relates to a method of achieving significantly improvement in the glycaemic control by a combined use of repaglinide and metformin in NIDDM patients poorly controlled on metformin alone.
Claims9
A method for treating NIDDM which comprises administering to a patient in need of such a treatment a short-acting hypoglycaemic agent which stimulates the insulin secretion selected from the group consisting of repaglinide and N-[(trans-4-isopropylcyclohexyl)-carbonyl]-D-phenylalanine supplemented with administration of a long-acting hypoglycaemic agent.
A pharmaceutical composition comprising repaglinide and metformin together with a suitable carrier.
Dependencies are inferred from the claim text.